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Tau protein aggregation into neurofibrillary tangles in the central nervous system
contributes to the etiology of certain neurodegenerative disorders, including Alzheimer’s
disease (AD). Though the mechanism of tau destabilization is not fully understood
yet, tau protein has been found to be hyperphosphorylated in tau aggregates. To
investigate this further, we developed a highly sensitive and specific mass spectrometry
(MS) method using parallel reaction monitoring (PRM) to identify tau phosphorylation
sites. This method enables us to compare the abundance of phosphorylation sites in
tau proteins in the brain and cerebrospinal fluid (CSF) in humans with and without
AD. We detected 29 distinct phosphorylated tau (p-tau) sites in full-length tau from
soluble human brain lysate and 12 sites on truncated tau in CSF, mainly in the
mid-domain. Brain soluble tau phosphorylation sites are localized on three domains
including a proline-rich mid-domain, the C-terminus, and a cluster on the N-terminal
projection domain not previously characterized. Some phosphorylation sites increased
in CSF, while others decreased compared to brain. Notably, phosphorylation on
T205 and S208, recognized by AT8 antibody defining Braak stages of brain tau
aggregation, were not detected in normal brain soluble tau but were found in the
CSF. Comparison of the p-tau rates from the brain and the CSF indicated that the
abundance of phosphorylated sites varied in a site-specific manner. CSF tau proteins
from non-AD participants were significantly hyperphosphorylated on T111, T205, S208,
T217 and T231. In AD CSF, hyperphosphorylation on these sites was exacerbated,
and phosphorylation on T153 and T175 specifically were detected. This supports the
hypothesis that tau hyperphosphorylation could be a physiological process amplified by
AD pathology. Conversely, we found that S202 was hypophosphorylated in CSF and was
not hyperphosphorylated in AD, demonstrating that p-tau isoforms could have different
metabolisms depending on which sites are phosphorylated. These site-specific p-tau
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rates are independent of tau concentration and distinct of current CSF tau and
p-tau assays measuring tau isoforms levels. Targeted MS multiplexing ability and
high-throughput capacity lets us envision the use of these new p-tau measurements
as promising biomarkers for AD diagnosis and tracking therapeutic responses.
Keywords: tau, phosphorylation, brain, mass spectrometry-LC-MS/MS, cerebrospinalfluid, parallel reaction
monitoring, quantification, Alzheimer’s disease
INTRODUCTION
Tau protein aggregation in the brain is one of the hallmarks
of neurodegenerative diseases called tauopathies, including
Alzheimer disease (AD), some frontotemporal dementia
(FTD), progressive supranuclear palsy (PSP), Pick’s disease,
and corticobasal degeneration (CBD). Normally a soluble
protein, there is a growing body of evidence associating
insoluble tau accumulation in the brain with cognitive decline
(Villemagne et al., 2015; Schöll et al., 2016). However, to
date, the biological and molecular pathways leading to the
abnormal tau proteins observed in the different tauopathies are
not well understood. One of the main hypotheses regarding
the origin of the pathogenesis of AD attributes abnormal tau
phosphorylation patterns to its disassembly from microtubules
and aggregation as paired helical filaments (PHF; Iqbal et al.,
2005; Wang and Mandelkow, 2016). Supporting this hypothesis,
abnormally-phosphorylated tau (p-tau) has been detected
in AD tau aggregates using phospho-specific antibodies
(Köpke et al., 1993; Braak and Braak, 1995; Augustinack
et al., 2002). Despite evidence that tau phosphorylation can
induce its self-assembly, the exact mechanism or the critical
phosphorylation sites are a matter of debate (Alonso et al.,
2001). In this context, understanding the qualitative as well
as quantitative aspects of tau phosphorylation at more than
80 potential phosphorylation sites is critical for dissecting
changes in the landscape of tau phosphorylation during
aggregation over the course of disease progression. Mass
spectrometry (MS) techniques enable a broad characterization
throughout the protein, with high specificity and quantitative
precision, which has been challenging using traditional
immunochemistry tools.
Over the last two decades, MS sequencing has been
primarily used to complement immunoassays for identifying
tau phosphorylation sites in tau aggregates (Hasegawa et al.,
1992; Hanger et al., 1998). The MS strategies employed have
mainly relied on data-dependent acquisitions (DDA), which have
provided valuable sequencing data to identify phosphorylated
sites (Hanger et al., 2007). However, this proteomic pipeline
may lead to stochastically missing tandem MS/MS spectra and
thus missing identifications when abundance is low or complex
co-eluted phosphorylated peptide patterns cannot be resolved.
Moreover, these experiments mainly provided qualitative,
dichotomous ‘‘detected/undetected’’ information. Consequently,
the abundance of phosphorylation at different confirmed and
putative sites and their potential quantitative changes under
physiological and pathological conditions remained unclear
or undefined.
Furthermore, the limited sensitivity associated with DDA
approaches has also prevented the use of MS to quantitatively
monitor tau phosphorylation in cerebrospinal fluid (CSF) in
which the concentration of tau is three orders of magnitude
lower than in the brain (Sato et al., 2018). Tau in the CSF
or extracellular tau is released from neurons under certain
physiological and pathological conditions (Yamada et al.,
2014) and reflects changes in brain intracellular tau (Sato
et al., 2018). However, relative tau phosphorylation changes
in the CSF are difficult to quantify using immunoassays due
to concomitant changes in unphosphorylated tau levels. For
example, in AD, tau phosphorylated at T181 (p-tau181)
and unphosphorylated, so called ‘‘total-tau’’ (t-tau) are
routinely measured by immunoassays; however, the ELISA
p-tau181/t-tau ratio does not report the changes in the
phosphorylation rate due to the nearly identical information
provided by the phospho-tau181 and t-tau ELISA assays
(correlations>0.95).
In 2011, the introduction of Quadrupole-Orbitrap hybrid
instruments allowed the design of new MS strategies including
parallel reaction monitoring (PRM; Gallien et al., 2012, 2014;
Peterson et al., 2012). PRM combines the high sensitivity,
high-throughput capability, and multiplex assaying of
targeted-MS experiments together with the specificity and
sequencing ability of high-resolution tandem MS. Applied to
tau isoforms measurement, PRM has led to new insights into
tau metabolism and truncation (Barthélemy et al., 2016; Sato
et al., 2018). We describe how MS using PRM experiments
opens new research avenues for understanding the physiology
of tau phosphorylation and its alterations in neurodegenerative
diseases, particularly in AD.
MATERIALS AND METHODS
Brain Soluble tau Extraction
Brain and CSF studies involving participants were approved by
the Washington University Human Studies Committee and the
General Clinical Research Center. Written informed consent was
obtained from all participants prior to inclusion in the study.
Brain soluble tau was extracted as described previously (Sato
et al., 2018). Briefly, frozen human brain tissues from controls
without amyloid and tau pathologies as described before (Sato
et al., 2018) were obtained from Knight Alzheimer’s Disease
Research Center (ADRC) at Washington University School
of Medicine (St. Louis, MO, USA). Sarkosyl-soluble tau was
separated from putative tau aggregates by ultracentrifugation as
reported in the literature (Hanger et al., 1998) and pooled. Frozen
human brain (200–400mg, frontal regions) were homogenized in
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FIGURE 1 | Principle of the parallel reaction monitoring (PRM) experiment.
Tris-HCl buffer (25mMTris-HCl, 150mMNaCl, 10mMEDTA,
10 mM EGTA, 1 mM DTT, phosphatase inhibitor Cocktail 3,
Roche Protease Inhibitor, pH 7.4. Final 3.25 mL/mg tissue)
on ice. Homogenates were centrifuged at 4◦C for 60 min at
11,000× g. The supernatant was solubilized in 1% Sarkosyl
for 60 min and centrifuged for 2 h at 100,000× g. Sarkosyl
soluble fractions were pooled and 50 µL fraction was diluted
10 times with 0.5% human plasma before immunoprecipitation.
For brain/CSF comparison, brain lysate pool was diluted from
500 to 8,000 times before immunopurification to match CSF
tau levels.
CSF tau Extraction
Human CSF was pooled from a cohort of 80 participants,
including amyloid negative and cognitively normal (CDR = 0)
controls (n = 47, age 60+) and amyloid positive and CDR> 0 AD
patients (n = 33, age 60+). Five and seven pools of 500 µL
CSF aliquots were generated from the control and AD groups,
respectively. At the time of initial collection, CSF was spun
down at 1,000× g for 10 min to remove cell debris and
immediately frozen at −80◦C. Protease inhibitor cocktail was
added during experiments. Tau was immunoprecipitated and
desalted as previously described with some modifications
(Sato et al., 2018). Briefly, CNBr-activated Sepharose beads
(GE Healthcare 17-0430-01) were crosslinked to antibodies
Tau1 and HJ8.5, separately at a concentration of 3 mg
antibody per gram of beads. Samples are spiked with AQUA
peptides (ThermoFisher Scientific) corresponding to 10 fmol
phosphorylated and 100 fmol unphosphorylated tau for each
sequence of interest per microliter of sample. Tau and p-tau
concentration is calculated using these internal standards.
Soluble tau was immunoprecipitated in detergent (1% NP-40),
chaotropic reagent (5 mM guanidine), and protease inhibitors
(Roche Complete Protease Inhibitor Cocktail). Anti-Tau1 and
HJ8.5 antibodies conjugated to sepharose beads were diluted
10 and 5-fold, respectively, in inactivated sepharose beads, and
30 µL of 50% slurry of the antibody beads were rotated with the
solution for 90 min at room temperature. The beads were washed
three times in 25 mM triethyl ammonium bicarbonate buffer
(TEABC, Fluka 17902). The bound tau was digested on-beads
with 400 ngMS grade trypsin (Promega, V5111) for 16 h at 37◦C.
Digests were loaded onto TopTip C18 (Glygen, TT2C18.96),
desalted, and eluted per manufacturer’s instructions. The eluted
peptides were dried by vacuum centrifugation (CentriVap
Concentrator Labconco) and were resuspended in 25 µL of
a solution of 2% acetonitrile and 0.1% formic acid in MS
grade water.
Mass Spectrometry
A 5 µL aliquot of the peptide resuspension was injected into
nano-Acquity LC for MS analysis. The nano-Acquity LC (Waters
Corporation, Milford, MA, USA) was fitted with HSS T3 75
µm × 100 µm, 1.8 µm column and a flow rate of 0.5 µL/min
of a gradient of solution A and B was used to separate the
peptides. Solution A was composed of 0.1% formic acid in MS
grade water and solution B was composed of 0.1% formic acid
in acetonitrile. Peptides were eluted from the column with a
gradient of 2%–20% of solution B in 28 min, then 20%–40%
solution B for another 13 min before ramping up to 85% solution
B in another 3 min to clean the column. The Orbitrap Fusion
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TABLE 1 | Brain/cerebrospinal fluid (CSF) pool phosphorylation rate comparison (HJ8.5+Tau1 IP-MS).
Phosphorylated site Peptide Isoform Brain lysate Brain lysate Normal CSF AD CSF
sequence soluble (1 ml 10×) soluble (1 ml 500×) (500 µl) (500 µl)
S46 45–67 1N/2N ? nd x x
T50 45–67 1N/2N 0.5 nd x x
T52 45–67 1N/2N 2.2 nd x x
S56 45–67 1N/2N 0.01 nd x x
S61/T63/S64 (2 sites minimum) 45–67 1N/2N 0.5/0.2 nd x x
S68 68–126 1N 1.4/0.3 nd x x
68–87 2N 0.3/0.05 nd x x
T69 68–126 1N 1.4/0.3 nd x x
68–87 2N 0.3/0.05 nd x x
T71 68–126 1N 0.2 nd x x
68–87 2N 0.02 nd x x
T76 68–87 2N 0.01 nd x x
T95 88–126 2N ? nd x x
T101 88–126 2N 0.06–0.22 nd x x
T102 88–126 2N 0.06–0.22 nd x x
T111 103–126 0N 0.02 nd 0.8 8.1
68–126 1N 0.2 nd x x
88–126 2N 0.07 nd x x
S113 103–126 0N 0.2 nd x low
68–126 1N 0.53 nd x x
88–126 2N 0.59 nd x x
T123 103–126 0N 0.02 nd x x
68–126 1N 0.02 nd x x
88–126 2N x nd x x
T153 151–155 all x nd x 0.8
T175 mc 171–180 all nd 0.1∗ x 0.1
T181 mc 175–190 all nd 9.5∗ 10.1∗ 13.3∗
S184/S185 181–190 all 0.1 nd x x
S199 (1) 195–209 all 0.29 1.3∗ 0.2∗ 0.2∗
S202 195–209 all 3.9 9.7∗ 2∗ 1.5∗
S199+S202 195–209 all 0.02 nd x x
S198+S202 195–209 all 0.01 nd x x
T205 195–209 all x x 2.3∗ 4∗
S208 195–209 all x x 0.001 0.003
T212 210–221 all ? nd x
S214 212–221 all 0.14 0.08 0.04 0.07
T217 212–221 all 0.43 0.5∗ 1.9∗ 8.5∗
T231 mc 226–234 all nd 0.1∗ 0.8∗ 1.4∗
S396 396–406 all 1.2 nd x x
S404 396–406 all 95 110∗ x x
S396+S404 mc 386–406 all nd nd x x
S409 407–438 all 0.3 nd x x
S411/S412/T413 (2 sites minimum) 407–438 all 1.2 nd x x
S416 407–438 all 1.0 nd x x
Number of unique sites 29 9 12
Values indicate phosphorylated/phosphorylated ratio in %. x, not detected. ∗measured using AQUA internal standards. nd, not determined. ?, not confidently assigned. (1) likely
underestimated due to lower recovery using Tau1 immunocapture.
Lumos was equipped with a Nanospray Flex electrospray ion
source (Thermo Fisher Scientific, San Jose, CA, USA). Peptide
ions sprayed from a 10 µm SilicaTip emitter (New Objective,
Woburn, MA, USA) into the ion source were targeted and
isolated in the quadrupole. These were then fragmented by HCD
and ion fragments were detected in the Orbitrap (resolution of
60,000, mass range 150–1,200 m/z). Monitoring of hydrophilic
peptides (SSRcalc <9, all without leucine) for peptide profiling
was performed on a HSS T3 300 µm× 100 µm, 1.8 mm column
at a flow rate of 4 µl/min with an elution occurring with a
2%–12% solution B gradient and a spray operating on a 30 mm
SilicaTip emitter.
Principles of PRM for p-tau Peptides
Discovery
Tau peptides containing hypothesized phosphorylation sites
were generated by digestion of protein from a tau-enriched
biological extract such as human brain soluble fraction.
These peptides are screened by targeted-MS analysis using
a quadrupole-orbitrap instrument, such as the Thermo
Fisher Orbitrap Lumos. For each phosphorylated peptide,
the selection of targeted-MS parameters such as precursor
mass, collision energy, or expected retention time is performed
in silico and refined using biophysical properties measured
for corresponding unmodified peptides that are much more
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FIGURE 2 | PRM screening of the mono-phosphorylated tau (p-tau) sequence at 103–126 (0N isoform). We identified a unique LC-mass spectrometry (MS)/MS
pattern eluting closely to the unmodified peptide 103–126 and containing fragment series expected for phosphorylation at T111 (a), S113 (b) or T123 (c).
Hypothetical y ion fragments from each p-tau peptide are underlined on the sequences. We deconvoluted the potential co-elution of the three putative
mono-phosphorylated peptides. Ion fragment y15 without phosphate is specific to the phosphorylated peptide on residue T111 [y15 (a)] and the y8 fragment with
phosphate is specific to p-tau peptide on residue T123 [y8 (c)]. Corresponding extracted ion chromatograms (XIC) are detected in low abundance above the limit of
detection, supporting the identification of the two corresponding mono-p-tau peptides. In contrast, the y15 fragment with phosphate, shared by pT111 and pS113
[y15 (a+b)], and the y8 fragment without phosphate, shared by pS113 and pT123 [y8 (b+c)], are much more abundant. These signal differences support the
existence of the tau peptide mono-phosphorylated at residue S113 (b) as the main component of the pattern.
abundant in the sample. For detecting phosphorylated peptides,
the quadrupole is set to select a mass window including the
hypothesized precursor mass. After precursor collision, all
generated fragments are simultaneously measured in the
Orbitrap over the time of chromatographic elution. Potentially
phosphorylated peptides can be searched in post analysis of
the generated data. Skyline software (MacCoss Lab, University
of Washington, WA, USA) was used to extract LC-MS/MS
data. The hypothetical peptide being screened is detected as
a LC-MS/MS fingerprint constituted by the strict co-elution
of the extracted masses from predicted MS/MS fragments
(Figure 1). The advantage of the PRM method over classic DDA
or targeted-MS methods is its ability to use the MS instrument
in the highest sensitive configuration possible and conserve
discovery capability.
Maximum sensitivity of the Quadrupole-Orbitrap instrument
during the screening is essential to detect minor ion fragments
and facilitates the identification of phosphorylated peptide
together with the localization of phosphorylated sites. Sensitivity
of the PRM measurement depends mainly on the number of
ions from the target of interest transferred into the Orbitrap
analyzer. This number was enhanced by increasing the fill time
used to acquire one MS/HRMS scan. The fill time corresponds to
the time spent to accumulate the targeted precursor mass from
the ion beam into the ion trap device. Accumulated precursors
are then fragmented and product fragments are transferred
into the Orbitrap to be analyzed. Thus, fill time is set to a
maximum limited by the need for a sufficient MS scan rate
to acquire enough data points to describe the chromatogram
signal (i.e., 8–15 scans per chromatographic peak). Fill time for
PRM screening on each investigated phosphorylated peptides
was typically set to 1 s.
Fill time is also limited by the risk of trap saturation.
This occurs when too many ions are sampled within the
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FIGURE 3 | PRM screening of mono-p-tau sequence 68–126 (1N isoform) containing six potential phosphorylation sites. Three phosphorylation sites are shared by
peptides containing residues 103–126 as described in Figure 2 (d–f). Six LC-MS patterns were identified. The Y28 fragment carrying phosphate, shared by pS68 (a)
or pT69 (b), is found in the two LC-MS patterns 4 and 5. This demonstrates the existence of the two phosphorylated peptides but corresponding LC-MS patterns
cannot be strictly assigned without the detection of ion fragment y29 to differentiate pS68 and pT69. Specific fragments corresponding to pT71 (c) and pT111 (d) are
found in LC-MS patterns 6 and 1, respectively. Specific fragments for pS113 (e) and pT123 (f; y15 with phosphate) are found in the LC-MS pattern 2. This pattern
contained both y10 fragments with and without phosphate, suggesting the co-elution of these two phosphorylated peptides. Since y10 without phosphate has the
major signal in comparison to y10 with phosphate, the degree of pT123 is likely lower than pS113. LC-MS pattern three is attributed to a minor conformer or LC
artifact from the phosphorylated peptide from pattern four as found for the non-phosphorylated peptide.
same scan and transferred to the Orbitrap, leading to
inaccurate mass measurement due to space charge effects.
To avoid such saturation, narrow precursor isolation
(0.7 Da) together with appropriate sample purification
(immuno purification) enriching the target over matrix
were chosen to decrease the contribution of potential
near-isobaric interferences.
Specificity of the PRM discovery experiment depends
on the resolving power of the LC-Q Orbitrap system.
Resolving power can be improved by different analytical
parameters, with the ultimate goal to obtain interference-free
LC-MS/MS fingerprints for the targeted peptides. This limits
the risk of ambiguous fragment assignment due to false
positive signals. Sample purification preferentially enriching
p-tau can also improve the specificity in the discovery of
minor p-tau peptides. High chromatographic peak capacity
and resolution limit the likeliness of co-elution. A narrow
quadrupole isolation window for the precursor decreases the
probability of interference on the MS/MS spectrum together
with limiting the risk of trap saturation as described above.
High Orbitrap resolution and analyzer calibration allow the
accurate extraction of mass fragments during data processing
limiting, the risk of transitions interference (Gallien et al.,
2012; Peterson et al., 2012). The choice of Orbitrap resolution
(60 k) is a balance between high resolution requiring more
acquisition time and reasonable scan rates compatible with the
chromatographic acquisition.
Quantitative Assessment of Site-Specific
Phosphorylation Rate of tau
To quantitatively assess the relative abundance of
phosphorylation of specific sites in tau from the brain
and CSF, we measured the extent of phosphorylation on
each site detected. We used three methods for this purpose:
(1) relative comparison between phosphorylated peptide isomers.
Signal comparison from transition ions are used to identify
each phosphorylated site. This can estimate the relative
abundance of each phosphorylated peptides sharing the
same sequence; (2) phosphorylated peptides are normalized
with the non-phosphorylated peptide as reference. LC-MS/MS
transition specific to each phosphorylated peptide is compared
to the corresponding transition from the non-phosphorylated
peptide. Each phosphorylated site ratio obtained can be
compared across the protein sequence. This strategy may
be biased by the difference in fragmentation efficiency
between the non-phosphorylated and the phosphorylated
peptides. This method cannot be applied when the
phosphorylated sites are part of a tryptic missed cleavage;
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FIGURE 4 | PRM screening of mono-p-tau sequence 45–67 (1N and 2N isoforms). A strong signal from a conformer was identified on the front of a
non-phosphorylated peptide LC-MS pattern. Thus, we predicted that corresponding LC-MS patterns for phosphorylated peptides would also have conformers
separable by LC. Indeed, PRM scan interpretation led to the detection of pT50 (b) as the main phosphorylation site on this sequence (pattern 2). Pattern 1, with a
similar fragmentation fingerprint, was attributed to a conformer of pT50. pS46 (a), able to differentiate signals from pT50 (b), was not detected, suggesting this
phosphorylation would be absent or low and co-eluted with other phosphorylated peptides sharing similar non-specific fragments. Co-elution of y9, y15 without
phosphate, and y17 with phosphate in LC-MS pattern 3 identified a phosphorylation on residue T52 (c). Patterns 4/6 and 5/7 were respectively paired as conformers.
Thus, two phosphorylated peptides could not be separated. Fragments found in these patterns were consistent with phosphorylation on one of the S61 (e), T63 (f),
and S64 (g) residues. MS/MS intensities were insufficient to identify the sites but at least two of these three sites were likely phosphorylated on this sequence.
Additionally, a minor y9 fragment without phosphate was found in the shoulder of pattern 7, which could be attributed to minor phosphorylation on residue S56 (d).
and (3) absolute quantitation using internal synthetic labeled
standards (i.e., AQUA) for each phosphorylated and
non-phosphorylated peptide. Signals from phosphorylated
and non-phosphorylated standards are used to define an
internal ratio. This strategy takes into account the fragmentation
specificity of each compared peptide but requires peptides
synthesis for each monitored species.
In this study, except for those including missed trypsin
cleavage, the second method was utilized to calculate
phosphorylation rates. We also applied the third method
(AQUA normalization) on a limited set of phosphorylated
sites found in both brain and CSF extracts when synthetic
phosphorylated peptides were available (i.e., T175, T181, S199,
S202, T205, T217 and T231) and one site found only in brain
(S404; Table 1). For AQUA measurement, brain extracts
were diluted 500–8,000 times to be comparable to CSF tau
levels. This dilution minimized the matrix effect that may
result from significantly different ratio of AQUA internal
standard to tau peptide levels in the brain vs. CSF. The first
method was used for initial interpretation of the complex
LC-MS/MS patterns from p-tau sequence containing numerous
phosphorylated residues.
Statistics
Data are represented as mean ± SD unless otherwise
specified. After confirming the normal distribution
of the data, one-way ANOVA followed by post hoc
analyses (Tukey test) were performed for comparing
tau phosphorylation rates. Additional statistical analysis
was completed using GraphPad version 8.0.1 (244) from
GraphPad Software Inc. Statistical significance between
relevant groups was determined with a two-tailed, unpaired,
Mann-Whitney t-test. Significance was evaluated at the
0.01 and 0.05 level.
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FIGURE 5 | PRM screening of mono-p-tau sequence 88–126 (2N isoform). Six potential phosphorylation sites are located in this sequence and six LC-MS patterns
were identified. Fragments found in pattern 1 and 2 were consistent with phosphorylated peptides at residues T111 (d) and S113 (e), respectively. No specific
fragment from the phosphorylated peptide at residue T123 (f) was found. Patterns 4 and 6 contained a low signal of the y29 fragment matching with phosphorylation
on residue T101 (b) or T102 (c), but no specific fragment able to differentiate them was detected. Patterns 3 and 5 shared fragments found in patterns 4 and 6 but in
lower abundance, locating the phosphorylated residue at the N-terminus on residue G109. This could indicate the presence of an additional phosphorylated peptide,
likely at residue T95 (a) or abundant conformers from peptides found in patterns 4 and 6.
RESULTS
Phosphorylation Sites on tau Protein in the
Normal Non-AD Human Brain
In order to determine phosphorylation sites of normal soluble
brain tau, extracts from healthy controls were purified by
immuno capture using Tau-1 and HJ8.5 tau antibodies
concentrating both phosphorylated and unphosphorylated
tau. The tryptic digestion of brain tau isoforms generated
27 unmodified peptides that were long and hydrophobic
enough to be detected by LC-MS (Barthélemy et al., 2016).
Twenty-five peptides contained serine and/or threonine as
potential phosphorylation sites. Several peptides contained
multiple potential phosphorylation sites (4–9) leading us to
consider different mono-phosphorylated peptides potentially
co-eluting together during the LC separation. After this,
the PRM screening method described above was applied to
these peptides.
The results from analysis of the projection domains in the
tau sequence (103–126) revealed multiple p-tau peptides
eluting into overlapping complex LC-MS/MS patterns
(Figures 2–6). We identified three phosphorylation sites
from the 0N isoform, the shortest isoform of the tau protein.
Although the LC system did not have the resolution for
differentiating the three phosphorylated peptides, fragment
identification and corresponding intensities were used to
deconvolute a signal composed of one major phosphorylation
site at residue S113, and two minor phosphorylation sites
at residues T111 and T123 (Figure 2). In contrast, when
screening tau sequences from the longer 1N and 2N isoforms,
further chromatographic separation was necessary to simplify
phosphorylated peptide elution patterns, especially when
multiple potential mono-phosphorylation sites were predicted
within the same peptide sequence (Figures 3–5). LC separation
allowed us to identify co-eluted, semi-specific MS/MS
fragments which contained differentially phosphorylated
residues. However, we have also identified a few signals
that could result from LC artifacts, likely due to dual
conformations of the same peptide in solution (Figure 4).
This effect was important for peptide sequence containing
amino acid residues 45–67 (in the 0N isoform) for both
unmodified and phosphorylated peptides (Figure 4) and
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FIGURE 6 | The PRM scan of mono-p-tau sequence 68–87, containing four potential phosphorylation sites. We detected three LC-MS patterns. Patterns 2 and
3 were consistent with phosphorylation at residues S68 (a) or T69 (b). Pattern 1 contained both fragments compatible with the presence of two co-eluted
phosphorylated peptides at T71 (c) and T76 (d). Comparison of y14 XIC with and without phosphate in pattern 1 indicates pT71 (c) is more abundant than pT76 (d).
less prevalent for sequences 68–126 (1N) and 88–126 (2N;
Figures 3, 5).
Phosphorylations at residues S113, T111 and T123 were
confirmed on peptide sequences 68–126 (1N) and 88–126 (2N).
In all cases, the S113 signal was the most abundant of the
three with a phosphorylation rate of 0.2%–0.5% (Figures 3, 5,
Table 1). Phosphorylations at residues T50, T52 and S56 were
clearly identified on the peptide sequence 45–67 (shared by
1N and 2N isoforms). On the same peptide, LC-MS signals
indicated at least two of the three residues (S61, T63, and
S64) were phosphorylated (Figure 4). No specific signals were
found to identify potential phosphorylation at residue S46.
Phosphorylation at residues S68 and T69 were evidenced in
sequences 68–126 (1N) and 68–87 (2N) but no specific fragments
were detected to differentiate their LC-MS patterns. On the same
1N and 2N peptide sequences, lower phosphorylation levels were
detected on T71. 2N specific phosphorylations on the T76, T101,
and T102 residues were also identified (summarized in Figure 7).
Induction of trypsin missed cleavage was also considered
for the screening of phosphorylated residues located after a
tryptic site as reported previously (sites T175, T181, S212,
T231 and S396; Hanger et al., 1998). Our PRM screening
successfully detected LC-MS patterns corresponding to p-tau
peptides already described in normal brain tissue by Hanger et al.
(1998; T181, S199, S202 and S404; Figure 7). Corresponding
LC-MS signals were high, suggesting that p-tau peptides
previously reported in normal human brains are likely the most
abundant. Our comparison of S199 and S202 phosphorylation
indicated a much more prevalent abundance of phosphorylation
at S202 (Figure 7). The use of an anti-Tau1 antibody for
tau extraction, associating with a non-phosphorylated epitope
on the 192–199 amino acid sequence, could explain the
low recovery of S199 phosphorylation in the extract. Given
the abundance of S202 and S404 phosphorylation in the
extract, we searched for the presence of di-phosphorylated
peptides from sequences 195–209 and 386–406. We detected
two LC-MS patterns with specific fragments corresponding to
double phosphorylation at S202/S199 and S202/S198 and one
LC-MS pattern corresponding to a double phosphorylation at
396/404 (Figure 7).
Additional screenings of soluble tau in brain extract
evidenced other less abundant mono-phosphorylated peptides
corresponding to phosphorylated residues at T175, S214,
T217, T231, and S396. Signals from fragments corresponding
to a phosphorylated peptide at S184 or S185 were also
detected at low levels when the mono-phosphorylated
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FIGURE 7 | Detection of phosphorylation sites in the mid-domain and C-terminus of brain p-tau protein.
peptide sequence 181–190 was screened (Figure 7). The
search for mono-phosphorylation on the long sequence
407–438 discovered a pattern consistent with phosphorylation at
residues S409 and S416 and at least one phosphorylation on the
group of residues S412/S413/T414.
Overall, we identified a minimum of 29 unique
phosphorylation sites detectable in the soluble tau fraction
extracted from normal non-AD brains using the PRM
screening method (Table 1). Twenty-five of them can be
unambiguously assigned to unique LC-MS signals and four
additional phosphorylation sites were evidenced without
assignment to the exact LC-MS patterns. These sites were
located on three clusters: a minimum of 14 phosphorylated sites
were located in the N-terminal projection domain, 10 on the
proline-rich domain in the middle of the sequence, and six on
the C-terminus.
Phosphorylation Sites on tau Protein in the
CSF
In comparison to the brain tau digest, CSF tau purification
using tau-specific antibodies and digestion generated detectable
peptides mainly from the mid-domain of the protein sequence
(residues 150–221). Peptides were detectable to a lesser extent
from the N-terminus, and almost no sequence was detectable
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FIGURE 8 | Phosphorylated peptide profiles from tau sequences 195–209 and 212–221 are variable between the soluble brain fraction, normal cerebrospinal fluid
(CSF), and Alzheimer’s disease (AD) CSF tau protein. Brain soluble tau extracts are diluted as indicated to approximately match corresponding CSF tau level.
Phosphorylated peptides on 195–209: in brain lysate, one signal corresponding to the co-elution of two phosphorylated peptides pS199 and pS202 is observed. In
CSF, two additional signals are observed. Fragment analysis allowed the assignment of the signal on left to pT205. In AD CSF, the two signals are increased allowing
the identification of specific fragments assigning the signal on the right to pS208. Phosphorylated peptides on 212–221: two signals with similar MS intensities
corresponding to pT217 and pS214 are identified in brain lysate. In CSF, the signal corresponding to pT217 is the most intense while pS214 is close to the limit of
detection, indicating a dramatic change in their relative abundance in comparison to the brain extract. In AD CSF, pT217 is significantly increased due to specific
hyperphosphorylation.
from the microtubule binding repeat (MTBR) domain or
the C-terminus of tau (Barthélemy et al., 2016; Sato et al.,
2018). This difference in signal recovery may result from tau
truncation during its release from neurons (Sato et al., 2018). The
peptide recovery of this mid-domain was sufficient to monitor
corresponding minor phosphorylated isoforms using the current
PRM method. Conversely, a significant technological advance in
MSmethod will be required to detect phosphorylated peptides in
the MTBR and C-terminal domains.
PRM screening of tau phosphopeptides from normal control
CSF identified several phosphorylation sites in common with
brain soluble tau at T181 (not shown), S199, S202 and
T217 (Figure 8). A low signal corresponding to pS214 was
also detected (Figure 8). A specific fragmentation pattern
corresponding to pT205 was identified in the CSF extract and
was separated by chromatography from the pS199/pS202 signals
(Figure 8).
To increase the probability of detecting additional
phosphorylated sites in CSF tau, we analyzed CSF pools
from AD patients with mild to moderate dementia. We expected
AD CSF pools would contain increased concentrations of tau
as well as increased levels of p-tau. The same phosphorylated
residues found in normal CSF (T181, S199, S202, T217 and T231)
were detected in AD CSF. Additionally, signals corresponding
to pS113 and pT175 previously found in tau from the brain but
not in the normal CSF were detected in AD CSF (Figures 8, 9).
A LC-MS/MS pattern containing specific fragments and distinct
retention times from S202/S199 phosphorylated peptides
allowed the identification of a new phosphorylated peptide
at S208. When we reexamined pS208 in normal CSF, we
detected the corresponding signal in low abundance. A LC-
MS/MS pattern matching with a new phosphorylated peptide at
residue T153 was detected close to the level of corresponding
unphosphorylated peptide (Figure 9). Careful reexamination
of brain extract data suggested the presence of a low abundant
signal corresponding to this site. Finally, we found specific
signals corresponding to phosphorylation on the 103–126 amino
acid sequence from the 0N isoform in AD CSF, indicating
S111 as the main phosphorylation site on this peptide, while
S113 was barely phosphorylated (Figure 10). Altogether,
12 phosphorylation sites were detected in CSF tau, two of which
were not detectable in brain lysate (Figure 11).
P-tau Abundance in Brain
In the brain, S404 was the most highly phosphorylated of
the examined phosphorylation sites (pS404/S404 = 110%,
i.e., 52% of S404 is phosphorylated). Thus, more than half
of the brain tau was phosphorylated at S404 compared to
other highly phosphorylated sites at S202 and T181 (9.7%
and 9.5%, respectively). 1.3% of S199 was phosphorylated
but this could be underestimated due to the inability of the
Tau1 antibody used for extraction to bind its corresponding
phosphorylated epitope (Liu et al., 1993). Phosphorylation on
C-terminal sites other than S404 was found to be around 1%.
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FIGURE 9 | pT153, pT175 and pT231 phosphorylated peptides identified in CSF. AQUA internal standard signals are shown for pT175 and pT231. Fragmentation
pattern of pT153 is similar to unmodified.
On the N-terminus, T52, S68/T69, T50, and S113 were also
phosphorylated with abundances ranging from around 0.5% to
2%. Other detected sites appeared to be phosphorylated at much
lower levels (<0.5%).
CSF p-tau Abundance Measurements
Highlight Differences Compared to the
Brain
In addition to the unique detection of pT205 and pS208 in CSF
tau but not brain, the relative phosphorylation abundance of
certain other phosphorylation sites detected in brain tau was
altered in comparison to control CSF tau (Figure 12). Compared
to brain, CSF tau phosphorylation was significantly lower at
sites pS199 (6-fold decrease, p = 0.008), pS202 (5-fold decrease,
p = 0.016), and pS214 (2-fold- decrease, p = 0.016). Conversely,
CSF tau phosphorylation was significantly higher at sites pT217
(4-fold increase, p = 0.016), pT231 (7-fold increase, p = 0.016)
and pT111 from 0N (16-fold increase). PT181 abundance was
similar in the CSF and the brain (∼10%). When measured in
AD CSF, pT175 remained low (0.1%–0.2% compared to 0.1%
in brain).
Brain and CSF tau have different truncation patterns: brain
tau isoforms are mainly full length while CSF tau isoforms
are truncated. Brain and CSF tau isoforms and corresponding
peptides recovered after IP depend on the antibody used
for the immunoprecipitation (Sato et al., 2018). Similarly,
antibodies used to immunoprecipitate tau could impact tau
phosphorylation recovery. To evaluate this impact on p-tau
recovery, we compared IP-MS results on phosphorylation rates
using different antibodies (Tau13, HJ8.5, HJ8.7, Tau1 and
Tau5) in addition to the Tau1+HJ8.5 combination (Figure 13).
A significant decrease of pS199/S199 ratio was observed when
Tau1 or Tau1+HJ8.5 were used in brain and CSF. This
suggests CSF truncation between the N-terminus and the
mid-domain could affect pS199 phosphorylation measurement
compared to brain. PS199/S199 rate measured in brain and
CSF with other antibodies appeared to be relatively similar.
Interestingly, some reactivity was still observed for pS199 in brain
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FIGURE 10 | Phosphorylation abundance on T111 is higher in the CSF than
the brain relative to S113 phosphorylation. In both brain and CSF, the MS/MS
fragment y18 common to all mono-phosphorylated peptides on tau
sequence 103–126 is detected. The relative abundance of the y15 fragment
from pS113 (b) is significantly lower in CSF in comparison to brain extract.
Inversely the y15 fragment from pT111 (a) is abundant in CSF and not
detectable in brain soluble extract diluted to match the AD CSF tau level.
extract and to a lesser extent in CSF, suggesting nonspecific
binding of Tau1, though S199 phosphorylation is present at
the end of the reported Tau1 epitope (192–199). The other
results were confirmed independent of the antibody used
for immunoprecipitation.
Since phosphatase activity during the post-mortem interval
(PMI) before autopsy can decrease tau phosphorylation
measured in brain extracts, we investigated the impact of
the PMI on phosphorylation rates commonly found in CSF
and brain extracts. Ten brains samples (middle frontal gyrus)
without tau pathology collected from participants with PMI
ranging from 5 to 16 h were analyzed. None of the brain extracts
originally analyzed had a PMI of greater than 16 h. We did
not find significant association (Spearman test, 95% confidence
interval, not shown) between PMI and phosphorylation
rates measured on T181, S199, S202, S214, T217, T231 and
S404 sites.
AD Specific p-tau Change in CSF
The increased CSF p-tau commonly reported in AD could be
the consequence of two potential effects: (1) the global increase
of tau regardless of its phosphorylation status; and (2) increased
hyperphosphorylation at specific sites. Normalizing p-tau signal
or level using non-phosphorylated tau allows for quantifying
changes in phosphorylation stoichiometry (i.e., hyper- or hypo-
phosphorylation) occurring at specific sites independently from
the global change in t-tau. The use of ‘‘hyper- and hypo-
phosphorylation’’ refers to a change in the ptau/tau ratio in
comparison to a ratio measured for a selected reference. For
example, we describe hyperphosphorylation of normal CSF in
comparison to brain measurements or hyperphosphorylation
of AD CSF in comparison to normal CSF. As we recently
demonstrated, soluble tau production is increased in AD
and correlates with amyloid plaques. Therefore, controlling
for not just the amount, but the rate of phosphorylation is
key to understand. pT181, pT217, pT231, pT205, pS208 and
pS214 were hyperphosphorylated in AD CSF as was 0N-specific
pT111 (Figure 12). PT153 and pT175 were not detected
in non-AD and likely increased slightly in AD. The sites
showing significant hyperphosphorylation compared to non-AD
were pT181 (p = 0.010), pS214 (p = 0.005), and pT217
(p = 0.003). pT181, pS214, and pT217 showed approximately
1.2-fold, 1.6-fold, and 4-fold increases in phosphorylation
respectively. Interestingly, not all the monitored sites were
hyperphosphorylated: pS199/S199 was not significantly changed
and pS202/S202 was significantly lower (p = 0.030) with an
approximately 1.2-fold decrease. Robustness of phosphorylation
ratios was assessed by incubating CSF for 16 h. Incubation
did not significantly affect tau phosphorylation ratio differences
observed between non-AD and AD CSF (Figure 14). Moreover,
absence of kinase activity on CSF tau was confirmed by the
non-detectability of phosphorylation on recombinant 15N-tau
spiked in CSF after incubation (not shown).
DISCUSSION
Technological Advancement of PRM on
p-tau Measurement
We report the most comprehensive qualitative and quantitative
analyses of p-tau in normal brain tissue and CSF to date.
Our approach contrasts with previous DDA studies on tau
phosphorylation which may not have captured potential minor
phosphorylation sites. However, our approach uses highly
sensitive targeted-MS in PRMmode to detect and quantify minor
phosphorylation. Phosphorylation site identification depends on
the careful manual interpretation of LC-MS/MS patterns to
identify co-elution of specific ion fragments for each examined
phosphopeptide. In prior studies, brain tau phosphorylation
has been mainly investigated in insoluble extracts enriched in
hyperphosphorylated tau from PHF and, to date, the most
detailed study has reported nine phosphorylation sites in
normal human tau protein (Hanger et al., 2007). Our in-depth
PRM data analysis detected more than 29 phosphorylated
residues with a majority being very low in abundance.
Indeed, the previously reported nine sites were amongst the
most abundant modifications in the protein. Application of
PRM analysis to normal CSF tau, present in much lower
abundance compared to the brain, led to the detection of
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FIGURE 11 | Relative abundance of tau phosphorylation depends on the biological extract and varies across the protein sequence. Comparison of tau
phosphorylation abundance measured by MS in normal brain lysate, normal CSF and AD CSF extracted by immunocapture using HJ8.5 and Tau1. Circle area is
proportional to site phosphorylation abundance. Red and green colors indicate an increase or decrease, respectively, in comparison to the brain soluble profile taken
as reference (blue). Tau is c-terminally truncated in CSF, which explains the absence of detection of the C-terminal cluster of phosphorylation sites. Phosphorylation
on T205 and S208 is specific to CSF (red X on Brain Soluble—top).
FIGURE 12 | Tau phosphorylation sites are differentially modified in brain, normal CSF and AD CSF. Measurements are the relative abundances of the
phosphorylated signal compared to the corresponding nonphosphorylated site (HJ8.5+Tau1 IP-MS). Brain results are obtained from diluted lysates from 500× to
8,000× factors to match the CSF tau level. Phosphorylations on T205 and S208 are undetectable in brain tissue. Phosphorylation on T111 is undetectable in 500x
diluted lysate but was detected in 10× diluted lysate with a corresponding abundance of 0.02%. Legend: ∗∗ indicates significance at p = 0.01 level and ∗ indicates
significance at p = 0.05 level.
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FIGURE 13 | Antibody effect on phosphorylation ratio measurement by IP-MS. Brain lysate pool, non-AD (n = 1) and AD CSF (n = 1) pools were
immunoprecipitated in parallel with antibodies against tau N-terminus projection domain (Tau13 or HJ8.5) or mid-domain (HJ8.7, Tau1 or Tau5). Radar plots of
phosphorylation ratios measured on main CSF sites (log10 scale) are shown in brain lysate (A), non-AD CSF (B) and AD CSF (C). (A–C) Tau phosphorylation ratio
measurements on pT181/T181, pT231/T231 are consistent across antibodies tested. PS199/S199 is decreased by using Tau1 or Tau1+HJ8.5 in comparison to
other antibodies. (D) Low recovery of pS199 by Tau1 or Tau1+HJ8.5 IP underestimate pS199/S199 ratio measurements compared to other antibodies tested.
Tau13, HJ8.5, and HJ8.7 antibodies indicate no significant changes of pS199 phosphorylation ratio between brain and CSF. Compared to brain, pS202/S202 CSF
hypophosphorylation (E) and pT217/pT217 hyperphosphorylation (F) are evidenced independently of the antibody used for IP-MS.
FIGURE 14 | CSF incubation does not impact phosphorylation rate
measurement on tau.
nine phosphorylation sites initially, with three additional sites
detected in AD CSF.
In addition to the significantly increased number of
phosphorylation sites detected, we demonstrated how sensitive
PRM screening enabled us to quantitatively assess the tau
phosphorylation rate or stoichiometry, independent of global
tau concentration. This concept is frequently overlooked but
critical in assessing changes in AD when absolute CSF
p-tau concentration may increase solely due to increase in
global tau isoforms concentration, and not due to change of
relative p-tau abundance. Phosphorylation rate measurement
from this study enabled for the first time the comparison of
the degree and distribution of phosphorylation rate changes
(hyper- vs. hypo-phosphorylation) across the protein, in different
compartments (intracellular brain vs. extracellular CSF), and in
different pathological conditions (AD vs. non-AD).
Some caveats of the PRM screening process are the low
throughput for discovery and the risk of missing p-tau species or
other post-translational modification (PTM) not hypothesized in
the study. Identifications from MS data can be further used in a
larger validation or clinical cohort to design scheduled LC-MS
methods, increasing multiplexing and throughput (Gillette and
Carr, 2013). Other proteases such as AspN could provide
a different set of tau and p-tau peptides than from trypsin
digest, allowing for a better coverage of tau, i.e., the C-terminal
domain (Hanger et al., 1998; Sato et al., 2018). The search
could be further refined by screening additional doubly- or
triply-phosphorylated tau peptides not considered in this study,
although their abundance may be minimal unless there is
biological coordination of site phosphorylation.
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Identification of a Cluster of
Phosphorylation Sites on the tau
Projection Domain
We found a cluster of previously undescribed phosphorylated
residues on the N-terminus projection domain of tau containing
alternative splicing-dependent peptides. Interestingly, this
domain was not previously found to be extensively
phosphorylated in PHF in the insoluble human brain fraction
(Hanger et al., 2007; Thomas et al., 2012; Funk et al., 2014;
Russell et al., 2016). This cluster was also not extensively
characterized in the recent comprehensive study performed in
mouse tau protein in the murine brain (Morris et al., 2015).
These discrepancies could be attributed to the difficulty of
characterizing complex mixtures of phosphorylated peptides,
distinguishable only by few specific MS/MS fragments and/or
subtle retention time shifting on LC. For example, S46 is the
only phosphorylated site previously reported in this domain in
normal human tau (Hanger et al., 1998). However, we did not
detect a specific signal for this species, which can be confounded
by search algorithms with neighboring phosphorylated sites at
T50 or T52, sharing a close fragmentation pattern. In this regard,
manual inspection is essential to clearly interpret and decipher
corresponding LC-MS/MS patterns for each phosphorylated
site. Another possible explanation of this discrepancy could be
the relatively low abundance of the N-terminal domain in PHF
in comparison to the MTBR domain, the mid-domain, and the
C-terminus (Mair et al., 2016).
This N-terminus projection domain has been recently
assigned as a part of the dominant component of the repulsive
barrier that prevents neighboring microtubules (associated to
tau via the MTBR domain) from getting close to each other
(Chung et al., 2016). This sequence contains numerous acidic
residues and an increase in phosphorylation may contribute
to increased global acidity, enforcing the repulsive barrier.
Together with a variable amount of N-terminal extension
induced by alternative splicing on exon 2–3, tau phosphorylation
could regulate tau/tau N-terminal interactions and microtubule
intermolecular distance.
Biological Implications of Different p-tau
Profiles in the Brain vs. CSF
Tau is mainly an intracellular protein that functions in
microtubule stability and was traditionally considered to only
be released extracellularly upon nerve injury or cell death.
However, recent studies have suggested that tau is secreted
under physiological and pathological conditions in a regulated
manner (Karch et al., 2012; Yamada et al., 2014). By comparing
soluble brain tau and CSF tau profiles in parallel to intracellular
and extracellular tau profiles and metabolism in neuronal
models, we have recently shown that tau secretion is an
active process that involves different turnover rates of tau
isoforms including truncated tau and p-tau (Sato et al., 2018).
Understanding the association between this active secretion
and phosphorylation of tau through comparison between
brain and CSF p-tau profiles provides potential insight into
AD pathogenesis.
We speculate that p-tau isoforms enriched in the CSF
have less affinity for microtubules and a higher likelihood
to be secreted. Inversely, p-tau isoforms impoverished in the
CSF could have more propensity to stay inside the neurons
and/or avoid cleavage. Our results demonstrate that several
phosphorylated residues are significantly enriched in the CSF
compared to brain extracts, such as T217, T231, T153 and
T111. All are proline-directed sites are potential substrates
of GSK-3β protein kinase, and may be subject to kinase-
dependent regulation. Unlike pT217, pS214 was not elevated in
the CSF compared to the brain. This extracellular enrichment of
pT217 over pS214 agreed with kinetic differences we previously
identified within cells for these isoforms (Sato et al., 2018), with
pT217 having a shorter turnover rate than unphosphorylated tau
and tau-pS214.
Alternatively, decreased phosphorylation observed on some
of the tau sites in brain extract compared to CSF could also
result from partial dephosphorylation occurring during the PMI
(Matsuo et al., 1994). Though such a decrease was not observed
within the 5–16 h PMI range, modification of phosphorylation
ratios during the PMI cannot be excluded. Assessing the kinetics
of dephosphorylation of these tau sites from brain biopsies byMS
would help to address the impact of this phenomenon on CSF
and brain comparisons in the future.
Conversely, pS202 was significantly lower in the CSF and
pS199 and pS202 were not elevated in AD, indicating that
these phosphorylations may promote tau sequestration inside
neurons. T181 is equally phosphorylated in the CSF and
the brain. pT205 and pS208 were exclusively detected in
CSF tau and not in soluble tau protein in the brain. This
is interesting considering that the triple phosphorylation at
S202, T205 and S208 is recognized by the anti-AT8 antibody
(Malia et al., 2016) commonly used to characterize Braak
stages of tau aggregation in brain (Braak and Braak, 1995).
Indeed, pS208 was detected by MS in PHF (Hanger et al.,
1998). pT205 and pS208 were absent in normal soluble
brain tau in our study, confirming the unlikeliness to detect
immunoreactivity of AT8 in normal brain tau. Furthermore, a
recent study implicates pT205 and pS208 as a combinational
phosphorylation pattern that, together with pS202, leads to tau
self-aggregation (Despres et al., 2017). Exclusive presence of
pT205 and pS208 in the CSF and further increased rates of
phosphorylation at both sites in AD could indicate a potential
protective clearance mechanism for neurons to remove these
pathology-prone p-tau species from the cells. Simultaneous
decrease of pS202 in AD CSF could also correspond to an
increased sequestration of associated isoforms when aggregated
with pT205 and pS208 in enriched AT8-positive tangles in
the AD brain. Alternatively, absence of phosphorylation on
pT205 and pS208 in brain extracts could result from their
specific degradation by phosphatases occurring during the
PMI. The rapid disappearance (<3 h) of AT8 reactivity
reported on tau, collected from brain biopsy, supports this
idea (Matsuo et al., 1994). Thus, such phosphatase activity
efficiently targeting pT205 and pS208 could also be seen as an
additional mechanism causing short a half-life of AT8-positive
material in neurons. The increase of pT205 and pS208 found
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in AD CSF would then indicate potentially pathological
decreasing of this protective mechanism. Finally, simultaneous
decrease of pS202 in AD CSF could also correspond to an
increased sequestration of associated isoforms when aggregated
with pT205 and pS208 in enriched AT8-positive tangles in
the AD brain.
We were unable to provide convincing detection of
phosphorylated residues from the MTBR domain in the soluble
fraction from normal brain. Phosphorylation sites on the MTBR
domain have been purported to reduce the affinity of tau
to microtubules (Biernat et al., 1993). The absence of such
phosphorylation in normal tau could support the abnormality
of these modifications found in PHF (Hanger et al., 2007).
CSF tau truncation restricts the examination of phosphorylation
changes in vivo since the MTBR domain likely degraded within
the cell after tau truncation (Kanmert et al., 2015), and so
was not recovered by the immuno-capture method used in
this study.
CSF p-tau Rates as AD Biomarkers
In addition to the significantly increased number of
phosphorylation sites detected, we demonstrated how tau
phosphorylation rate or stoichiometry can be quantified
independent of global tau concentration. This concept
is frequently overlooked but critical in assessing CSF
tau phosphorylation changes in AD when absolute CSF
p-tau concentration may increase solely due to increased
t-tau concentration (i.e., pT181), and not due to an increase in
the relative phosphorylation rate itself. Phosphorylation rate
measurements from this study enabled for the first time the
comparison of the degree and distribution of phosphorylation
rate changes (hyper- vs. hypo-phosphorylation) across the
protein, in different compartments (intracellular brain vs.
extracellular CSF), and in different pathological conditions (AD
vs. non-AD). This method could be used in the future to look
at modifications of AD brain phosphorylations on numerous
sites across brain regions and Braak stages as recently performed
using immunochemistry (Neddens et al., 2018).
In this study, we demonstrated that tau in ADCSF is generally
hyperphosphorylated in comparison to non-AD CSF. However,
the degree of hyperphosphorylation is site dependent. T111,
T205, S208 and T217 were more hyperphosphorylated than
T181, which is the most commonly measured target used as
a p-tau biomarker for AD (Fagan et al., 2009). We have also
identified T153 phosphorylation that was exclusively found in
AD CSF. Interestingly, the sites found hyperphosphorylated in
AD CSF correspond to the sites already significantly increased
in normal CSF compared to the brain (ie T111, T205, S208,
and T217, and to a lesser extent T231). This would indicate
AD pathology exacerbates cellular mechanisms contributing
to specific p-tau isoforms enrichment during tau release into
the CSF. Overall, the high magnitude of change found on
these sites lets us envision their use as sensitive biomarkers
to detect AD. Our study relied on a limited number of CSF
pools and future studies on larger CSF cohorts would better
establish potential relationships between p-tau changes and
brain amyloidosis and tau aggregation over the course of the
disease. We can also ask whether there are any specific p-tau
profile changes in other non-AD tauopathies such as PSP, CBD,
and FTD. Alternatively, this method could be used to track
different kinase activities in vivo and in vitro and may also
provide a promising tool to assess new drugs targeting abnormal
tau metabolism.
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